Pain Therapeutics' Remoxy Would Be A Good Fit For Any Of These Experienced Companies
Clinically Sound Investor - at Seeking Alpha - Wed Dec 03, 2:41PM CST
MNK: 94.72 (-0.36), JNJ: 104.43 (-2.29), ENDP: 68.77 (-2.45), ACT: 259.00 (-4.00), DRRX: 0.87 (+0.03), NVS: 93.52 (-0.82), PTIE: 1.86 (+0.08)
Alzheimer's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcdctm/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 210 companies are cited in this text including: - AB Science - AbbVie Inc. - AC Immune SA - CHA Bio & Diostech Co., Ltd. - Chase Pharmaceuticals Corporation - Clera Inc. - Eli Lilly and Company - EncephRx, Inc. - EndoCeutics, Inc. - Epigen Biosciences, Inc. - MediPost Co., Ltd. - Neuralstem, Inc. - Pain Therapeutics, Inc. - PALUMED S.A. - Panacea Pharmaceuticals, Inc. - PeptiDream Inc. - Peptron, Inc. - Pfizer Inc. - PharmatrophiX, Inc. - Pharnext SAS - Phenomenome Discoveries, Inc. - PhysioGenix, Inc. - Plexxikon Inc. - Prana Biotechnology Limited - Probiodrug AG - Proteome Sciences Plc - Suven Life Sciences Ltd. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/xcdctm/alzheimers
PFE: 30.95 (-0.70), LLY: 69.55 (-2.06), ABBV: 65.27 (-1.76), PRAN: 1.86 (-0.05), PTIE: 1.86 (+0.08), CUR: 2.58 (-0.09)
Painkiller Remoxy (Oxycodone) May Still See An NDA Refiling By Mid-2015
Clinically Sound Investor - at Seeking Alpha - Tue Nov 25, 10:24AM CST
PTIE: 1.86 (+0.08)
President of Proove Biosciences, Brian Meshkin, Speaks at the 8th Annual Pain Therapeutics Summit
PRWeb - Tue Nov 11, 9:06AM CST
President and CEO of Proove Biosciences, Brian Meshkin, spoke at the 8th Annual Pain Therapeutics Summit on the Emerging Role of Genetics in Pain Management. The Annual Pain and Migraine Therapeutics Summit is the premier conference covering the field of pain research and emerging therapeutic methods. The event attracts leaders from the pharmaceutical, biotech, device and medical communities to learn about the cutting-edge advances in various treatments of pain. Mr. Meshkin was among a panel of speakers including key industry leaders and academic researchers concerning the latest drug discovery science and analysis of pain therapies.
PTIE: 1.86 (+0.08)
Pain Therapeutics lowers earnings 250% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 1:14PM CST
PTIE: 1.86 (+0.08)
Pain Therapeutics - Drugs, Markets and Companies
PR Newswire - Mon Nov 03, 7:02AM CST
Research and Markets has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.
PTIE: 1.86 (+0.08)
Pain Therapeutics' (PTIE) CEO Remi Barbier on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 8:37PM CDT
PTIE: 1.86 (+0.08)
Pain Therapeutics Reports Q3 2014 Financial Results
GlobeNewswire - Thu Oct 30, 3:51PM CDT
Pain Therapeutics, Inc. (Nasdaq
PTIE: 1.86 (+0.08)
Pain Therapeutics EPS of -$0.08
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:50PM CDT
PTIE: 1.86 (+0.08)
Nasdaq stocks posting largest volume increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LAYN: 8.22 (+0.46), TRNX: 26.39 (-0.14), DRRX: 0.87 (+0.03), CEMI: 4.30 (+0.03), PBCP: 10.50 (+0.10), PTIE: 1.86 (+0.08), AMDA: 0.69 (-0.01)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.31 (-0.14), KSS: 57.27 (+0.37), MU: 34.00 (-1.19), PFE: 30.95 (-0.70), HAL: 37.93 (-0.30), AMGN: 164.53 (-1.55), NQ: 5.35 (-0.09), RGC: 20.87 (+0.02), MS: 36.25 (-1.15), MSG: 72.52 (-0.13), NVAX: 5.76 (-0.17), CQB: 14.46 (+0.01), SRPT: 13.97 (-0.33), RCPT: 120.08 (-1.38), TWTR: 37.10 (+0.40), PTIE: 1.86 (+0.08)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:49AM CDT
GFA: 1.59 (-0.04), FST: 0.36 (-0.04), ZAZA: 1.46 (-0.13), EBR: 2.03 (+0.01), VTAE: 22.01 (+0.30), XGTI: 1.02 (-0.04), VBIV: 3.48 (-0.03), DRRX: 0.87 (+0.03), CEMI: 4.30 (+0.03), PBR: 7.11 (-0.31), CBDE: 0.90 (+0.06), OMEX: 1.00 (-0.02), LAYN: 8.22 (+0.46), SRPT: 13.97 (-0.33), CNIT: 4.30 (+0.09), AKBA: 11.33 (+0.25), CTP: 14.76 (+0.31), VPCO: 1.31 (+0.04), PTIE: 1.86 (+0.08)
Pfizer (PFE) Stock Falls After Dropping Pain Drug
at The Street - Mon Oct 27, 10:37AM CDT
Shares of Pfizer (PFE) are down after the pharmaceutical company decided to discontinue its agreement to develop and commercialize the drug Remoxy, an oral formulation of oxycodone.
PFE: 30.95 (-0.70), PTIE: 1.86 (+0.08)
Durect and Pain Therapeutics plunge after Pfizer backs out of Remoxy development
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:26AM CDT
PFE: 30.95 (-0.70), DRRX: 0.87 (+0.03), PTIE: 1.86 (+0.08)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:13AM CDT
GFA: 1.59 (-0.04), PBR.A: 7.57 (-0.41), VNDA: 12.72 (-0.17), ELP: 12.91 (+0.41), DRRX: 0.87 (+0.03), NBG: 1.79 (-0.01), NQ: 5.35 (-0.09), CEMI: 4.30 (+0.03), VIV: 17.58 (-0.54), PBR: 7.11 (-0.31), BBD: 12.83 (-0.61), NVAX: 5.76 (-0.17), SRPT: 13.97 (-0.33), GOL: 5.43 (-0.24), DGLY: 15.55 (+1.34), ITUB: 12.62 (-0.61), GPRO: 60.52 (+0.47), ERJ: 35.23 (-0.99), EBR: 2.03 (+0.01), CBD: 37.12 (-0.62), CIG: 4.90 (+0.03), CPL: 13.77 (-0.29), RNA: 18.76 (-0.21), VALE: 7.19 (-0.07), SBS: 6.54 (-0.03), AEZS: 0.60 (+0.03), PAY: 33.01 (-1.47), PTIE: 1.86 (+0.08)
DURECT Provides Update on REMOXY® and POSIDUR(TM) Programs
PR Newswire - Mon Oct 27, 7:05AM CDT
DURECT Corporation (Nasdaq: DRRX) reported today that Pfizer Inc. (NYSE: PFE) announced today that it has notified Pain Therapeutics, Inc. (Nasdaq: PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize REMOXY® (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics. As a result, Pain Therapeutics has the rights to develop and commercialize REMOXY on its own or with an alternative licensee. Pain Therapeutics had the rights to develop and commercialize this product candidate under a license from DURECT.
PFE: 30.95 (-0.70), DRRX: 0.87 (+0.03), PTIE: 1.86 (+0.08)
Pfizer to Discontinue Agreement on REMOXY(TM) (oxycodone) Extended-Release Capsules CII
Business Wire - Mon Oct 27, 7:02AM CDT
Pfizer Inc. (NYSE
PFE: 30.95 (-0.70), PTIE: 1.86 (+0.08)
Pain Therapeutics to Regain Full Rights to REMOXY(R)
GlobeNewswire - Mon Oct 27, 7:00AM CDT
Pain Therapeutics, Inc. (Nasdaq
PFE: 30.95 (-0.70), PTIE: 1.86 (+0.08)
Pain Therapeutics reports October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 6:15PM CDT
PTIE: 1.86 (+0.08)
Pain Therapeutics to Host Conference Call to Discuss Q3 2014 Financial Results
GlobeNewswire - Thu Oct 23, 5:00PM CDT
Pain Therapeutics, Inc. (Nasdaq
PTIE: 1.86 (+0.08)